Welcome to our dedicated page for Quanterix news (Ticker: QTRX), a resource for investors and traders seeking the latest updates and insights on Quanterix stock.
Quanterix Corporation (NASDAQ: QTRX) generates news that spans scientific breakthroughs, clinical research, corporate developments, and financial performance, all centered on its ultra-sensitive Simoa biomarker detection technology and spatial biology capabilities. As a life sciences company active in testing laboratories and professional scientific services, Quanterix regularly reports on studies, collaborations, and product launches that affect disease research and diagnostics.
Investors and researchers following QTRX news will see coverage of peer‑reviewed studies that rely on Simoa assays, such as large population-based analyses of Alzheimer’s Disease Neuropathological Changes using p‑Tau 217, and multiple sclerosis research that combines GFAP and NfL biomarkers for personalized monitoring. These articles illustrate how Quanterix assays and reference databases are applied in real-world clinical and epidemiological settings.
The company also issues updates on new assay launches and platform enhancements, including commercial introductions of p‑Tau 205 and p‑Tau 212 assays for Alzheimer’s research, and developments at the Quanterix Accelerator Laboratory, which supports clinical testing and global clinical trials. News items may highlight regulatory milestones, such as clinical laboratory permits and medical device registrations for specific assay kits in various markets.
From a corporate and capital markets perspective, Quanterix news includes quarterly financial results, non‑GAAP performance metrics, and commentary on integration progress following its acquisition of Akoya Biosciences. Filings and press releases discuss cost synergies, revenue composition across product and service lines, and governance changes such as cooperation agreements with shareholders and Board structure updates.
This QTRX news page brings together these updates so readers can track scientific publications, diagnostic advancements, spatial biology integration, and financial disclosures in one place.
Lucent Diagnostics (NASDAQ: QTRX) partnered with Life Line Screening to offer Lucent’s non-invasive blood-based biomarker test nationally, with programs already underway in Florida, California, and Texas. Life Line Screening will use its mobile model to provide testing at community venues and share results to help primary care physicians enable earlier intervention.
Life Line Screening operates in the 48 contiguous states and hosts over 15,000 community events annually, supporting scalable access to testing for Alzheimer’s disease risk and MCI.
Quanterix (Nasdaq: QTRX) said its executive leadership will participate in two investor conferences in March 2026: the 46th Annual TD Cowen Healthcare Conference and the Leerink Global Healthcare Conference 2026. Fireside chats and one-on-one meetings are scheduled with webcasts available.
TD Cowen fireside chat: March 4, 2026 at 11:50 am ET. Leerink fireside chat: March 9, 2026 at 1:00 pm ET. According to the company, live and recorded webcasts will be available on the Investors section of the company website.
Quanterix (Nasdaq: QTRX) will report fourth quarter and full year 2025 financial results on March 2, 2026. The company will issue a press release after market close and host a conference call at 4:30 p.m. ET the same day to discuss the results.
Investors can join via dial-in (800-715-9871 or 646-307-1963, conference ID 7904928) or via live webcast on the company website; an archived replay will be available for one year.
Quanterix (Nasdaq: QTRX) submitted a 510(k) premarket notification to the FDA for a multi-analyte algorithmic blood test to aid detection of Alzheimer’s disease in patients with cognitive symptoms. The test uses Simoa technology and a five-analyte panel (p-Tau217, Aβ42, Aβ40, GFAP, NfL) and is supported by clinical evidence from over 1,800 symptomatic patients across three cohorts and prior Breakthrough Device designation.
The submission aims to offer a non-invasive, quantitative assessment of amyloid, tau, neuroinflammation, and axonal damage to improve diagnostic clarity, especially in early-stage cases.
Quanterix (NASDAQ: QTRX) highlighted a JAMA Network Open study showing a multi‑analyte blood panel—measuring Aβ42/Aβ40, p‑Tau217, GFAP, and NfL with Simoa® technology—better predicts progression from subjective cognitive decline (SCD).
The Amsterdam UMC study followed nearly 300 individuals for up to 15 years and reported an optimal multi‑analyte model C‑index of 0.90, while a single baseline multi‑marker measurement outperformed standalone p‑Tau217. Quanterix notes the same biomarkers are used in its LucentAD Complete multi‑analyte laboratory test.
Quanterix (NASDAQ: QTRX) announced that on January 15, 2026 it granted inducement awards to four new employees under its 2025 Inducement Plan in reliance on Nasdaq Listing Rule 5635(c)(4). The grants comprise 88,050 RSUs and options to purchase an aggregate of 125,745 shares at an exercise price of $7.95 per share (the closing price on the grant date). RSUs and options vest 25% after one year, then monthly over 36 months; options have a 10-year term. Awards were approved by the Compensation Committee.
Quanterix (NASDAQ: QTRX) highlighted a Nature study using its Simoa p-Tau 217 assay on a Norwegian cohort of 11,000+ individuals aged 58+. The study reports age-stratified Alzheimer’s Disease Neuropathological Changes (ADNC) rising from 10% at 58–69.9 to 64.9% in those >90, and finds 30.4% ADNC in people aged 70+, with 11.4% preclinical AD, 10.8% prodromal AD, and 7.4% AD dementia. Researchers state ~10% of the 70+ population meet current treatment eligibility. Results used a validated commercial p-Tau 217 kit on an automated HD-X analyzer, aiming to improve population-level prevalence estimates and planning for therapies and trials.
Quanterix (NASDAQ: QTRX) announced publication in the journal Brain of a landmark study showing a dual-biomarker blood-test approach for multiple sclerosis (MS). The research found serum GFAP levels were significantly associated with higher risk of Progression Independent of Relapse Activity (PIRA), while serum NfL continued to predict future relapses and acute inflammatory activity. The study used the automated HD-X and the Simoa Neurology 2-Plex B kit and leveraged large Simoa-derived normative databases from thousands of individuals. An online interpretive tool adjusts for age, sex, and BMI to enable individualized clinical interpretation and monitoring.
Quanterix (NASDAQ: QTRX) reported third-quarter 2025 results for the period ending September 30, 2025, with revenue of $40.2M, up 12.3% year-over-year, and GAAP gross margin 42.8% (adjusted gross margin 45.9%).
The company highlighted post‑Akoya integration progress, capturing $67M of cost synergies and projecting $85M annualized synergies and cash‑flow breakeven in 2026. Adjusted EBITDA loss was $11.9M; cash and equivalents totaled $138.1M with expected year‑end cash of ~$120M. 2025 revenue guidance reiterated at $130–$135M (pro forma $165–$170M); adjusted cash use expected $34–$38M.
Quanterix (NASDAQ: QTRX) will report third quarter 2025 financial results and host a conference call on Monday, November 10, 2025 at 4:30 p.m. ET. The company will release a press release with its Q3 2025 results after market close on November 10, 2025, posted on its website.
Investors can join the live call by dialing (800) 715-9871 or (646) 307-1963 with conference ID 3186071, or listen via live webcast on the Quanterix Investors News & Events page. An archived replay will be available on the company website for one year.